Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Pyxis Oncology stock | $11.77

Learn how to easily invest in Pyxis Oncology stock.

Pyxis Oncology, Inc. is a biotechnology business based in the US. Pyxis Oncology shares (PYXS) are listed on the NASDAQ and all prices are listed in US Dollars. Pyxis Oncology employs 38 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Pyxis Oncology

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PYXS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pyxis Oncology stock price (NASDAQ: PYXS)

Use our graph to track the performance of PYXS stocks over time.

Pyxis Oncology shares at a glance

Information last updated 2021-10-12.
Latest market close$11.77
52-week range$11.72 - $19.00
50-day moving average $12.60
200-day moving average $12.60
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-6.51

Buy Pyxis Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pyxis Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pyxis Oncology price performance over time

Historical closes compared with the close of $11.77 from 2021-10-15

1 week (2021-10-12) -0.08%
1 month (2021-09-15) N/A
3 months (2021-07-15) N/A
6 months (2021-04-15) N/A
1 year (2020-10-15) N/A
2 years (2019-10-15) N/A
3 years (2018-10-15) N/A
5 years (2016-10-15) N/A

Pyxis Oncology financials

Gross profit TTM $0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation $374.2 million

TTM: trailing 12 months

Pyxis Oncology share dividends

We're not expecting Pyxis Oncology to pay a dividend over the next 12 months.

Pyxis Oncology overview

Pyxis Oncology, Inc. , a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

What percentage of Pyxis Oncology is owned by insiders or institutions?
Currently 6.077% of Pyxis Oncology shares are held by insiders and 0.032% by institutions.
How many people work for Pyxis Oncology?
Latest data suggests 38 work at Pyxis Oncology.
When does the fiscal year end for Pyxis Oncology?
Pyxis Oncology's fiscal year ends in December.

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site